| Drug Name |
Siponimod |
| Drug ID |
BADD_D02511 |
| Description |
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020.[L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label].
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings.[L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] |
| Indications and Usage |
This drug is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults [FDA label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AA42 |
| DrugBank ID |
DB12371
|
| KEGG ID |
D11460
|
| MeSH ID |
C578989
|
| PubChem ID |
44599207
|
| TTD Drug ID |
D07FKQ
|
| NDC Product Code |
0078-0986; 0078-0979; 0078-1014 |
| UNII |
RR6P8L282I
|
| Synonyms |
siponimod | 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethylbenzyloxyimino)-ethyl)-2-ethylbenzyl)-azetidine-3-carboxylic acid | Mayzent | BAF312 | BAF-312 |
